1. Introduction {#s0005}
===============

A hallmark of cardiovascular disease (hypertension, myocardial infarction, heart failure and malignant ventricular arrhythmia) is cardiac autonomic dysregulation ([@bb0205]). The phenotype of impaired parasympathetic responsiveness and sympathetic hyperactivity in experimental animal models ([@bb0440], [@bb0340], [@bb0680], [@bb0505]) is also well documented in large scale human studies in the setting of heart failure and myocardial infarction, and is predictive of morbidity and mortality ([@bb0400], [@bb0545]). Despite advances in emergency revascularisation strategies for myocardial infarction, device therapy for heart failure and secondary prevention pharmacotherapies, mortality from malignant ventricular arrhythmia remains high. Patients at highest risk or those with haemodynamically significant ventricular arrhythmia can be treated with implantable cardioverter defibrillators (ICD) ([@bb0065], [@bb0500], [@bb0075]), but the morbidity and reduction in quality of life due to the burden of ventricular arrhythmia and shock therapy persists. Therefore, future therapies must aim to target the underlying pathophysiology that contributes to the generation of ventricular arrhythmia. Emerging evidence now suggests that modulation of the autonomic nervous system with neuro-axis targeting is gaining utility as a novel therapy in this patient group ([@bb0040], [@bb0665]).

2. The integrated heart-brain neuro-axis {#s0010}
========================================

The autonomic nervous system functions to tightly regulate cardiac excitability and contractile function ([@bb0250]). The interconnected architecture has been elegantly explored and described by Ardell and Armour ([@bb0060]) based upon physiological data from multiple studies across varying spatial domains. This system is considered as a manifestation of three levels of neural hierarchy, moving away from the historical reciprocal thesis of cardiac control where the two arms of the ANS acted as 'accelerator and brake' on cardiac function. Instead, the excitability of cardiac parasympathetic pathways or sympathetic pathways depends on tonic inputs to synaptic junctions at several stages in the brain, spinal cord and in the extrinsic and intrinsic cardiac ganglia ([@bb0225], [@bb0360], [@bb0210]). Level 1 encompasses the spinal cord and medulla with higher centre modulation ([@bb0475], [@bb0265]). Level 2 incorporates extracardiac neurons such as the stellate ganglia ([@bb0050], [@bb0055], [@bb0030]) and level 3 includes all the intrinsic cardiac ganglia and nerves ([@bb0060]). Cardiac afferents and extracardiac circulatory receptors serve to transmit beat to beat sensory information to levels 1 and 2 and processing at these levels allows feedback loops which maintain physiological electrical and contractile stability in normal and stressed states ([@bb0040]).

In the setting of cardiovascular disease or cardiac injury such as myocardial infarction, neurophysiological changes take place at distinct levels in the neural circuitry ([@bb0600], [@bb0715]). Effects at the level of the organ such as scar formation and fibrosis contribute to heterogeneities in electrical activation and may contribute to the creation of fixed and functional substrate for re-entrant arrhythmia ([@bb0675]). There is also afferent mediated activation of neurohumoural systems and increased sympathetic stimulation and reduced vagal tone ([@bb0745]). In the short term, this is an adaptive response to maintain cardiac output ([@bb0365]), although at the cost of increased myocardial oxygen demand. However, following the acute injury phase, there is continued abnormal cardiac afferent signalling resulting in a maladaptive environment of persistent sympathetic activity ([@bb0810]) that contributes to remodelling and the progression of cardiac disease that can ultimately lead to fatal arrhythmia.

Understanding of this complex cardiac neural-axis has led to targeted autonomic modulation therapies for heart failure and arrhythmia aimed at the cervical cardiac vagus and sympathetic nervous system respectively ([@bb0040]). This review explores recent advances in mechanistic research in both limbs of the ANS and potential avenues for translation into clinical therapy. In addition, we also discuss the relationship of these findings in the context of the reported efficacy of current neuromodulatory strategies in the management of ventricular arrhythmia.

3. Mechanisms of ventricular arrhythmia {#s0015}
=======================================

An understanding of the mechanisms responsible for the initiation and maintenance of ventricular arrhythmia is critical if effective treatment strategies are to be investigated and developed. The principle contributing factor to the onset of arrhythmia is re-entry. Fibrillation occurs when an electrical wave-break induces re-entry and leads to a sequence of new wave-breaks ([@bb0220], [@bb0750], [@bb0760]). Wave-break is affected by static and dynamic factors and these influence the likelihood of local wave-break resulting in re-entry. Static factors are predominantly anatomical such as scar and fibrosis and lead to tissue heterogeneity and electrical remodelling that is fixed. Key components of dynamic factors are changes in membrane voltage and intracellular calcium, which are influenced by the autonomic nervous system and act synergistically with static factors to destabilise electrical activation ([@bb0750]).

4. The effects of sympathetic stimulation on cardiac electrophysiology {#s0020}
======================================================================

Contemporary research has led to a spectrum of neuro-axial therapies in the setting of patients at high risk of malignant ventricular arrhythmia. This has been based on mechanistic evidence from models of sympathetic hyperactivity at the level of the organ in animals ([@bb0250]), and more recently from human studies ([@bb0665]).

The effect of sympathetic stimulation on global ventricular electrophysiology has been studied extensively in animal models ([@bb0460], [@bb0535]) and humans ([@bb0725]). In the rabbit heart in-vitro, sympathetic stimulation using an electrode inserted in the spinal canal produces regional apex-base changes in restitution kinetics ([@bb0460], [@bb0535]). This is presumably mediated by regional differences sympathetic innervation and I~Ks~ distribution, potentially influencing the vulnerability to arrhythmia. The ability of local changes in sympathetic activity to trigger ventricular arrhythmias is well established ([@bb0520]). Epicardial injection of NE in the pig elicits triggered automaticity, and computational modelling implicated a Ca^2 +^ overload mechanism, supporting the hypothesis that heterogeneity or gradients of activation are pro-arrhythmic. The functional effect of post myocardial infarction remodelling has been elegantly demonstrated in patients undergoing endocardial and epicardial mapping as part of therapeutic catheter ablation procedures ([@bb0720]). The effect of direct adrenergic stimulation with isoproterenol or reflex sympathetic stimulation in response to baroreflex activation elicites regional changes in repolarisation dynamics. This includes abnormal neural control in remote areas where a lack of action potential duration (APD) shortening in response to baroreflex activation suggests functional denervation. These results were reproduced in a porcine model of myocardial infarction following direct stellate ganglia stimulation ([@bb0015]). Interestingly, histological and molecular analysis of stellate ganglia tissue from these animals also demonstrates remodelling with increased tyrosine hydroxylase staining ([@bb0585]). This has been replicated in studies on stellate ganglia tissue from patients undergoing sympathectomy for refractory ventricular arrhythmia ([@bb0010]).

5. Efferent cardiac sympathetic neurotransmission in health and disease {#s0025}
=======================================================================

A growing body of work has demonstrated that sympathetic hyperactivity associated with several cardiovascular diseases resides, at least in part, with dysregulation in post-ganglionic cardiac sympathetic neurons. This is of particular interest as this area is perhaps more easily accessible for therapeutic intervention compared to the brainstem. Emerging evidence suggests that impaired NO and intracellular calcium handling are key intermediaries in sympathetic dyautonomia, since these abnormalities can be seen prior to the onset of the disease phenotype itself. For example, hypertension is associated with neurohumoral activation ([@bb0190], [@bb0775]) resulting in decreased parasympathetic responsiveness ([@bb0410]), sympathetic hyperactivity ([@bb0120], [@bb0455], [@bb0240]) and increased norepinephrine (NE) release ([@bb0605]). Post-ganglionic sympathetic neurons from the stellate ganglia of spontaneously hypertensive rats (SHRs) have a greater depolarisation-evoked intracellular Ca^2 +^ transient compared to normotensive controls. The Ca^2 +^ profile was observed in cells from neonatal, young pre-hypertensive and adult hypertensive animals suggesting the molecular phenotype is well conserved ([@bb0430]). Moreover, the neuronal Ca^2 +^ current is increased in neurons from the SHR indicating that dysregulation of ion channel physiology contributes to the alteration in Ca^2 +^ transients ([@bb0435]). In addition, neuronal NE uptake by the NE uptake transporter (NET) is also decreased in stellate neurons from the SHR ([@bb0645]), thereby contributing to the increased NE spill over and heightened sympathetic responsiveness in both the adult ([@bb0315]) and young SHR before they develop high blood pressure ([@bb0650]). Of interest, the sympathetic phenotype can be rescued with site-specific nNOS gene transfer in tyrosine hydroxylase positive neurons ([@bb0740]) resulting in a reduction in Ca^2 +^ transients and inhibition of neurotransmission.

5.1. How does nNOS confer its protective effects? {#s0030}
-------------------------------------------------

Cytosolic nNOS translocates to caveolae post myocardial infarction and this is facilitated by its own shuttle adaptor protein, NOS1-AP/CAPON ([@bb0090]). NOS1AP provides an interesting potential mechanistic link between cellular physiology and arrhythmia as GWAS studies have linked single nucleotide polymorphisms (SNPs) in the gene for NOS1-AP with QT variation ([@bb0045]) and sudden cardiac death ([@bb0765]) in the general population. These SNPs are also risk factors for sudden cardiac death in patients with inherited long QT syndrome ([@bb0160], [@bb0690]). NOS1AP is highly expressed in sympathetic neurons from the stellate neurons and is down regulated in the SHR ([@bb0435]). Overexpression of NOS1-AP in the SHR increases nNOS activity without a change in nNOS expression itself resulting in a reduction in neuronal Ca^2 +^ transients and NE release ([@bb0435]). These effects are abolished by nNOS inhibition, indicating a functional role for NOS1-AP in the NO mediated modulation of neurotransmission and therefore may represent a novel therapeutic target for modulating the gain of sympathetic activity in high risk populations ([@bb0425]).

5.2. Interaction with neurotrophic factors {#s0035}
------------------------------------------

It is interesting that sympathetic neuronal hyperactivity begins prior to the development of the disease phenotype and continues as the disease progresses. Sympathetic nerves project into the myocardium along with the parasympathetic innervation and together with sensory fibres act to tightly regulate cardiac function ([@bb0210]). The density of innervation corresponds to physiological triggers such as neurotrophins, of which nerve growth factor (NGF) is a prototypic member. NGF is upregulated in cardiac hypertrophy ([@bb0385]) and also after myocardial infarction in a canine model ([@bb0795]), leading to heterogeneous hyperinnervation. The relevance of this to arrhythmia was demonstrated by NGF infusion after myocardial infarction which resulted in an increased incidence of ventricular arrhythmia and sudden cardiac death ([@bb0125]). However, NGF also plays a role in the development of sensory innervation, and afferents responsible for the transduction of stimuli such as hypoxia, acidosis and pain during myocardial ischaemia ([@bb0325]). Sensory innervation has been shown to be impaired in conditions such as diabetes mellitus and may contribute to the phenomenon of silent myocardial ischaemia and the genesis of malignant ventricular arrhythmia ([@bb0200]). Direct gene transfer of NGF into diabetic rat hearts improved cardiac sensory innervation ([@bb0335]) and recombinant NGF has been shown to be safe when administered to diabetic patients with polyneuropathy ([@bb0025]). Pathways such as this require further study to determine the contrasting effects on sensory innervation and potential deleterious effects of heterogeneous hyper-innervation seen post myocardial infarction. An alternative approach is to target the chondroitin sulfate proteoglycans present in scar tissue following MI which prevents sympathetic reinnervation by binding the neuronal protein tyrosine phosphatase receptor σ (PTPσ). Targeting PTPσ either genetically or pharmacologically restores sympathetic innervation to the scar and markedly reduces arrhythmia susceptibility in the immediate post-MI period ([@bb0215]).

There are also chronic temporal changes in innervation that take place during disease progression in heart failure. Chronic sympathetic hyperactivity and exposure to NE leads to a reduction in NGF, and in severe decompensated heart failure, loss of innervation is seen (anatomic denervation). Heart failure is also associated with changes in other inflammatory and neurohumoural pathways including a range of growth factors and cytokines. Candidate molecules include leukemia inhibitory factor (LIF) and members of the interleukin (IL-6) family ([@bb0250]). These molecules can induce changes in stellate ganglia neurons with increased expression of cholinergic markers via a gp130 signalling pathway ([@bb0355]). This trans-differentiation process is of unknown significance, but there are data from murine studies of hypoxia induced heart failure in which sympathetic nerve specific gp130 knockout had adverse outcomes compared to controls indicating a potential protective role. A recent study also demonstrates neural remodelling including increased nNOS expression in a porcine model of chronic myocardial infarction model particularly in the ventral interventricular ganglionated plexi, dorsal root ganglia and stellate ganglia ([@bb0515]). The spatio-temporal features of changes in cardiac innervation continue to be the subject of study and may yield an alternative therapeutic approach in modifying the risk of ventricular arrhythmia.

6. The *anti*-arrhythmic effect of the vagus: historical perspective and emerging mechanistic insights {#s0040}
======================================================================================================

Efferent vagal innervation of the heart is classically thought to be only concentrated in the sinoatrial, atrial and atrioventricular nodal regions. Advances in anatomical techniques have however challenged the historical perspective that this innervation is restricted to the atria and structures in the conduction system ([@bb0590], [@bb0415]). Immunohistochemical techniques identifying either acetylcholinesterase (AChE) and more recently choline acetyltransferase (ChAT) have led to revisions in this dogma, where significant cholinergic epicardial and endocardial innervation of atria and ventricles across a range of mammalian species has been observed ([@bb0105], [@bb0560], [@bb0080], [@bb0705]). There is however considerable species variation in sites of preganglionic nerve terminations in parasympathetic ganglia ([@bb0550], [@bb0670], [@bb0150]) and this may underlie some of the species dependent variation in response to VNS reported in the literature. Despite a sparse innervation of the ventricle in a variety of species, functionally VNS can produce a decrease in left ventricular contractility in human subjects ([@bb0420]).

The *anti*-fibrillatory effect of the vagus was first described in 1859 ([@bb0185]) and elegant studies have demonstrated that VNS decreases the occurrence of ventricular arrhythmia during CAO, ischaemia-reperfusion and also in the absence of structural heart disease ([@bb0375], [@bb0155], [@bb0510], [@bb0395], [@bb0780]). The most compelling demonstration of the anti-fibrillatory effect of VNS and the importance of vagal tone has come from Peter Schwartz and colleagues. They employed a canine model of healed anterior myocardial infarction at increased risk of malignant ventricular arrhythmia. Animals were subjected to increasing workload on a treadmill post-infarction with concurrent occlusion of the circumflex artery resulting in VF in 60% of animals ([@bb0630], [@bb0635]). Animals that survived this stressor had increased vagal tone indicated by a reduction in heart rate during exercise, and this protective effect was abolished by muscarinic blockade with atropine. Direct VNS in the same model system also resulted in a significant reduction in VF occurrence ([@bb0710]).

The mechanistic basis of this *anti*-fibrillatory property of VNS can be considered in terms of the effect on static and dynamic contributors to the development of ventricular arrhythmias. Tissue heterogeneity due to scar and fibrosis after myocardial infarction is a key substrate for the initiation and maintenance of re-entry and ventricular tachycardia ([@bb0675]). Uniform activation of the ventricle is dependent upon gap junction distribution and function. Alteration in gap junction expression is seen in the context of ischaemia, HF and cardiomyopathy and these groups are at high risk of ventricular arrhythmia. Ando et al. ([@bb0020]) demonstrated that VNS resulted in maintenance of gap junction function as evidenced by preservation of phosphorylated connexin 43 and an 87% reduction in post myocardial infarction ventricular tachycardia (VT) in rats. Similar results have been reported by Sabbah ([@bb0610]) where chronic VNS resulted in normalisation of connexin 43 expression in a canine model of micro-embolisation induced HF. These pre-clinical observations of positive remodelling of substrate by VNS are exciting observations and clinical studies with VNS in HF patients may be able to assess this effect via complex imaging studies. Inflammatory pathways play a key role in fibrosis ([@bb0540]), scar formation and hypertrophy ([@bb0390]). VNS in the canine HF model normalises levels of IL-6 and TNFα ([@bb0735]) and chronic VNS reduces plasma levels of angiotensin II ([@bb0790]), another potent pro-fibrotic mediator.

6.1. The direct and indirect effect of VNS on sympathetic signalling and a direct effect on ventricular electrophysiology {#s0045}
-------------------------------------------------------------------------------------------------------------------------

Stimulating the cardiac vagus results in bradycardia and some studies have suggested that the *anti*-arrhythmic effect is attenuated if the heart rate is controlled ([@bb0235], [@bb0375], [@bb0380], [@bb0510], [@bb0805]), although recent data ([@bb0115], [@bb0350]) has demonstrated that an anti-fibrillatory property of cholinergic signalling persists independent of heart rate. Nitric oxide (NO) plays a key role in mediating vagal bradycardia and its mechanism is site-specific ([@bb0555]). Depolarisation of nerve terminals leads to release of acetycholine (ACh) which binds to sino-atrial node (SAN) cell muscarinic receptors (M~2~) coupled to inhibitory G proteins ([@bb0625]). This leads to hyperpolarisation via stimulation of ACh-activated K^+^ channels, reduction in adenylate cyclase (and therefore cAMP), with subsequent decrease in the hyperpolarisation-activated current, I~f~, and PKA dependent phosphorylation of the L-type calcium current, I~CaL~, thereby reducing diastolic depolarisation and heart rate ([@bb0405]). Neuronal NOS (nNOS) is thought to be the critical source of NO in modulating vagal neurotransmission. This mechanism was suggested by the observation that NO donors ([@bb0290]) and inhibitors of NOS and soluble guanylyl cyclase (sGC) ([@bb0300]) do not affect the heart rate response to ACh in vitro. In addition, application of ACh to atria from nNOS knockout mice also remains intact despite impaired vagal responses ([@bb0130]). Release of radio-labelled ACh from field stimulated atria is also increased by NO donors and abolished by sGC inhibitors ([@bb0290]), further supporting a pre-synaptic, autocrine role rather than direct co-transmitter function in terms of vagal control of heart rate. Mechanistically, NO augments parasympathetic transmission by augmenting pre-synaptic cAMP-PKA regulation of N- and P-type calcium channels by a cGMP-PDE3 mediated increase in cAMP which phosphorylates N-type channels leading to an increase in ACh release ([@bb0305]).

Recent data has demonstrated that the *anti*-fibrillatory effect of direct VNS is independent of heart rate but still dependent on NO ([@bb0115]). The potential for a direct effect of VNS on ventricular electrophysiology has been studied in a series of experiments utilising a Langendorff perfused rabbit heart with intact bilateral vagal innervation. Left or right VNS flattened the action potential duration (APD) restitution curve and prolonged ventricular effective refractory period (ERP) ([@bb0525]) in keeping with the anti-arrhythmic mechanism suggested by the restitution hypothesis ([@bb0755]). A more defined anti-fibrillatory effect was also demonstrated by determining ventricular fibrillation threshold (VFT) to remove the confounding effect of heart rate reduction. VFT was increased with left or right VNS despite differential heart rate reductions seen from each limb ([@bb0530]), and in contrast to the earlier studies of VNS, these observations were seen in the absence of background sympathetic stimulation. This would support a direct ventricular effect rather than dependence on indirect 'accentuated antagonism' of adrenergic signalling. The pattern of ventricular repolarisation was also reversed with bilateral VNS ([@bb0530]), although the mechanistic significance of this remains uncertain and requires further investigation.

The dogma of vagal or cholinergic signalling has been that release of ACh from cholinergic nerve terminals results in activation of M~2~ ACh receptors (AChR) and downstream coupling to G~i~, eNOS and G~k~ signalling cascades. G~i~ inhibits adenylyl cyclase and thereby reduces cAMP dependent stimulation of L-type Ca^2 +^ current (LTCC) and phosholamban. M~2~ dependent stimulation of eNOS activity has also been proposed as a mechanism for accentuated antagonism of β-receptor stimulation when cAMP levels are already elevated ([@bb0070], [@bb0255]). Generation of NO via this pathway may increase sGC generation of cGMP via stimulation of PDE2 ([@bb0260]). The role of the pathway is controversial ([@bb0305]) and many groups have observed antagonism of heart rate and contractility to be intact despite genetic deletion of eNOS ([@bb0465]). M~2~ receptor activation of G~k~ increases I~KACh~ and many propose that this is the main mechanism by which cholinergic accentuated antagonism is mediated ([@bb0485]).

In the innervated, rabbit heart preparation described above, the *anti*-fibrillatory effect of direct left or right VNS was interestingly maintained in the presence of atropine, but abolished with non-specific NOS inhibition and restored with supplementation of [l]{.smallcaps}-arginine, the substrate for NOS ([@bb0110], [@bb0115]). This suggests a non-receptor dependent, nitrergic anti-arrhythmic mechanism of VNS. The release of NO was confirmed with an increase in epicardial DAF-2 fluorescence. The effect of VNS on APD restitution was also lost with NOS inhibition, but the effect on ERP was maintained, suggesting divergent pathways mediating these effects on ventricular electrophysiology. Central modulation of rat vagal signalling via optogenetic silencing of preganglioninc neurons from the dorsal ventral motor nucleus ([@bb0470]) demonstrates some beneficial effects on electrophysiology. During central silencing of DVMN with combined β-blockade and muscarinic blockade, reductions in ventricular ERP and VT could be abolished by NOS blockade with 7-nitroinidazole ([@bb0445]) suggestive of paracrine NO signalling. Others however, observe contrasting results ([@bb0350]). Using an isolated rat heart preparation, stimulation with an ACh analogue, carbamylcholine (CCh) that is resistant to cholinesterase, results in an increase in VFT independent of heart rate. CCh perfusion also resulted in prolongation of APD during fixed rate pacing and flattening of the APD restitution curve that is consistent with an *anti*-arrhythmic effect. This rise in VFT was also dependent upon the generation of NO as the effect was abolished by non-selective and neuronal NOS blockade and downstream blockade of sGC. CCh perfusion also increased NO metabolites (NOx), and this was prevented by mecamylamine, a specific inhibitor of the nicotinic AChR demonstrating that the source of NO was neuronal.

Therefore, observations in the rat are in keeping with the observations in the rabbit that nNOS derived NO is a key component of the anti-arrhythmic effect of cholinergic signalling. However, in the rat the anti-fibrillatory effect is abolished by atropine in keeping with the established autocrine role of NO ([@bb0290]). Furthermore, an NO donor, can increase VFT, an effect abolished by atropine, indicating that NO was acting upstream of the muscarinic receptor. The most likely mechanistic explanation of these observations is the nNOS derived NO from parasympathetic ganglia facilitates ACh release from sites of ganglionic projections via a cGMP-PDE3 dependent pathway increasing PKA dependent phosphorylation of N-type calcium channels ([@bb0290]), but this may be dependent on the density of innervation and the expression or activity of the nNOS enzyme.

Notwithstanding the above observations, these data must also be considered within the limitations of the model systems studied. Sensory fibres make up to 70% of the cervical vagus ([@bb0095]) and they will also be recruited with direct stimulation of the transected nerve and may influence the generation of nNOS derived NO. The relevance of afferent fibre stimulation has been assessed in a porcine model of VNS with and without nerve transection ([@bb0770]). Here VNS without decentralisation activates afferent fibres in the ipsilateral vagus nerve with accompanying reflex inhibition of cardiac parasympathetic efferent electrophysiological and haemodynamic effects. Furthermore, the species dependent variation in parasympathetic projections may also contribute to the relative importance of the two proposed pathways. However, the critical role of muscarinic receptors is supported by the CCh experiments and this is in keeping with established literature ([@bb0155], [@bb0780], [@bb0710], [@bb0170], [@bb0175]) and recent studies of VNS in ischaemia-reperfusion ([@bb0660]).

The *anti*-arrhythmic role of NO in mediating vagal protection is supported by studies across multiple domains, and future studies will need to further delineate the sites of action and optimum strategies to exploit this effect therapeutically. Speculatively, a nicotinic receptor based NO mediated mechanism that converges on the muscarinic receptor is conceivably amenable to a more targeted approach with gene therapy or a pharmacological treatment strategy. Percutaneous cardiac gene transfer of nNOS increases vagal neurotransmission and bradycardia ([@bb0490]) and reduces mortality three days post myocardial infarction in the guinea pig ([@bb0165]). Whether gene transfer of nNOS into cardiac cholinergic ganglia provides a direct *anti*-fibrillatory action on the ventricle that could be used therapeutically remains to be established, although gene transfer of nNOS into the pig cervical vagus increases cardiac baroreflex sensitivity ([@bb0275]).

7. Neuromodulation targeting the cervical vagus nerve {#s0050}
=====================================================

Targeting the cardiac vagus with device therapy for heart failure is a recent example of a translational bench to bedside research. The first in man trial of vagus nerve stimulation (VNS) ([@bb0180]) was a small, proof of concept study that demonstrated an improvement in symptoms in patients with advanced heart failure treated with VNS. However, larger, clinical studies such as ANTHEM-HF ([@bb0580]) and NECTAR-HR ([@bb0785]) have yielded disappointing results in terms of echocardiographic and clinical end points. A larger, randomised clinical trial, INOVATE-HF ([@bb0270]) has also recently reported no impact on heart failure events or mortality in patients with ejection fractions \< 40% and New York Heart Association (NYHA) class III symptoms ([@bb0230]). It is worth highlighting that these trials employed a variety of different stimulation currents and frequencies, different stimulation timings (continuous v′ R wave synchronised bursts) as well as different approaches (left verses right) all of which can impact on the efficacy of the treatment ([@bb0370], [@bb0035]). Trials to date have focused on cardiac imaging and heart failure symptoms, but of considerable mechanistic interest may be the potential role for appropriate VNS in suppressing ventricular arrhythmia.

8. Neuromodulation directly targeting the cardiac sympathetic nervous system {#s0055}
============================================================================

The potential of the vagus nerve as a therapeutic target in heart failure continues to be the subject of clinical trials, but challenges remain in delivering effective device therapy. Historically, pharmacological approaches such as cholinesterase inhibition ([@bb0085], [@bb0615]) have also been limited. Therefore the sympatho-adrenal axis has been the principal target for established pharmacotherapies such as β-blockers and ACE inhibitors, with both achieving significant reductions in morbidity and mortality ([@bb0345], [@bb0145], [@bb0575], [@bb0135]). However, sudden cardiac death (SCD) remains a significant clinical problem and sympathetic activation is a key contributor in patients with and without structural heart disease. Recent observations have led to neuro-axial therapies directly targeting the sympathetic nervous system in the setting of VT due to structural heart disease and channelopathies ([@bb0655]). Patients can present with VT that is recurrent or incessant, resulting in haemodynamic compromise, multiple ICD shocks and high mortality ([@bb0730]). Conventional management strategies include trials of anti-arrhythmic medications and catheter ablation ([@bb0565]), but recurrence of arrhythmia is common ([@bb0700]). Neuromodulation by directly targeting the sympathetic nervous system has demonstrated efficacy in animal and human studies and the commonest strategies employed are thoracic epidural anaesthesia and cardiac sympathetic denervation by stellectomy (CSD) ([@bb0450], [@bb0005]). In the largest case series to date, 41 patients underwent left or bilateral stellectomy for refractory ventricular arrhythmia and failed catheter ablation ([@bb0725]). The majority of patients were taking anti-arrhythmic drugs and 73% were taking β-blockers. CSD resulted in almost 50% of patients being free of ICD shocks at 1 year with the remaining experiencing a significant reduction in arrhythmic events. A similar approach has been used successfully in long QT syndrome ([@bb0495], [@bb0640]) and catecholaminergic polymorphic VT ([@bb0140]). In a series of 17 patients with LQTS or CPVT undergoing left CSD for recurrent arrhythmia despite β-blockade in all, 87% of patients had a significant reduction in arrhythmic events following LCSD. In the setting of VT storm, thoracic epidural anaesthesia ([@bb0450]) which acts to modify sympathetic outflow rather than remove neurotransmitter source, has also demonstrated efficacy.

9. Indirect neuromodulation of cardiac sympatho-vagal balance {#s0060}
=============================================================

Other approaches to reducing cardiac sympathetic drive include targeting higher centres via deep brain stimulation (DBS). DBS of the periaqueductal grey is a treatment for chronic pain can also lead to increases or decreases in blood pressure depending on the location of the electrode ([@bb0245], [@bb0570])and alter heart rate variability ([@bb0570]) and baroreflex sensitivity by influencing sympathetic outflow ([@bb0685]). Spinal cord stimulation at the level of T1--3 not only reduces cardiac sympathetic drive but also targets neural processing via intrathoracic extra-cardiac and intrinsic cardiac ganglia, as well as local circuit neurons ([@bb0040]). In early human trials, continuous spinal cord stimulation improved symptoms and left ventricular dimensions in patients with severe symptomatic heart failure ([@bb0695]) but not when administered intermittently ([@bb0800]). Afferent signalling can also be targeted via denervating the carotid body ([@bb0480], [@bb0620]) or via renal sympathetic nerve ablation ([@bb0195]) in order to reduce cardiac sympathetic drive. Renal denervation can have beneficial effects on cardiac electrophysiology in animal models ([@bb0330]) and has been used to treat VT storm in patients ([@bb0595]), despite the disappointing results of the Symplicity-HTN3 trial in drug resistant hypertension ([@bb0100]).

10. Conclusions {#s0065}
===============

Although neuromodulation therapies offer promise in terms of treatment of ventricular arrhythmias, it is interesting to note that most to date have been trialed in patients already taking the maximally tolerated doses of β-blockers ([@bb0280]). The mechanistic basis of neuromodulation therapies may be found in emerging evidence of the role of factors produced within the microenvironment of the heart, its vasculature and between neuronal populations influencing local sympatho-vagal balance. These neuromodulators may reside within neurones (such as nNOS and NOS1-AP) or be mediators that are co-transmitted with NE such as ATP, neuropeptide Y (NPY) and galanin, or ACh such as vasoactive intestinal peptide (VIP). NPY and galanin have been shown to be released with high-level sympathetic nerve stimulation and reduce cholinergic ACh release and bradycardia ([@bb0310], [@bb0320]). In addition NPY may act directly on ventricular myocytes to trigger arrhythmias independent of beta-receptor stimulation ([@bb0285]). Cardiac myocytes and the vasculature also release a variety of mediators such as angiotensin II and natriuretic peptides which may influence neuronal physiology in a paracrine manner ([@bb0295]), and these crosstalk and paracrine pathways converge on neuronal and myocyte Ca^2 +^ handling, thereby potentially influencing arrhythmogenesis. Neuromodulation therapies may not only remove the source of the principal neurotransmitter, but also influence the local release of co-transmitters providing increased efficacy over conventional medical therapies. The functional significance of these pathways and potential therapeutics avenues in disease states is yet to be established.
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